These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33715173)

  • 1. Peripheral CB1R as a modulator of metabolic inflammation.
    Han JH; Kim W
    FASEB J; 2021 Apr; 35(4):e21232. PubMed ID: 33715173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice.
    Han JH; Shin H; Park JY; Rho JG; Son DH; Kim KW; Seong JK; Yoon SH; Kim W
    FASEB J; 2019 Mar; 33(3):4314-4326. PubMed ID: 30566396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic potential of second and third generation CB
    Cinar R; Iyer MR; Kunos G
    Pharmacol Ther; 2020 Apr; 208():107477. PubMed ID: 31926199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.
    Cooper ME; Regnell SE
    Br J Clin Pharmacol; 2014 Jan; 77(1):21-30. PubMed ID: 23452341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.
    Tam J; Vemuri VK; Liu J; Bátkai S; Mukhopadhyay B; Godlewski G; Osei-Hyiaman D; Ohnuma S; Ambudkar SV; Pickel J; Makriyannis A; Kunos G
    J Clin Invest; 2010 Aug; 120(8):2953-66. PubMed ID: 20664173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications.
    Nagappan A; Shin J; Jung MH
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.
    Jourdan T; Demizieux L; Gresti J; Djaouti L; Gaba L; Vergès B; Degrace P
    Hepatology; 2012 Mar; 55(3):790-9. PubMed ID: 21987372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CB
    Drori A; Gammal A; Azar S; Hinden L; Hadar R; Wesley D; Nemirovski A; Szanda G; Salton M; Tirosh B; Tam J
    Elife; 2020 Nov; 9():. PubMed ID: 33210603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J mice.
    Tang Y; Ho G; Li Y; Hall MA; Hills RL; Black SC; Liang Y; Demarest KT
    PLoS One; 2012; 7(8):e42134. PubMed ID: 22870290
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Hirsch S; Tam J
    Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31096702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.
    Knani I; Earley BJ; Udi S; Nemirovski A; Hadar R; Gammal A; Cinar R; Hirsch HJ; Pollak Y; Gross I; Eldar-Geva T; Reyes-Capo DP; Han JC; Haqq AM; Gross-Tsur V; Wevrick R; Tam J
    Mol Metab; 2016 Dec; 5(12):1187-1199. PubMed ID: 27900261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.
    Nguyen T; Thomas BF; Zhang Y
    Curr Top Med Chem; 2019; 19(16):1418-1435. PubMed ID: 31284863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MECHANISMS IN ENDOCRINOLOGY: Endocannabinoids and metabolism: past, present and future.
    Simon V; Cota D
    Eur J Endocrinol; 2017 Jun; 176(6):R309-R324. PubMed ID: 28246151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic potential of targeting the peripheral endocannabinoid/CB
    Tam J; Hinden L; Drori A; Udi S; Azar S; Baraghithy S
    Eur J Intern Med; 2018 Mar; 49():23-29. PubMed ID: 29336868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocannabinoids regulate adipokine production and the immune balance of omental adipose tissue in human obesity.
    Ge Q; Maury E; Rycken L; Gérard J; Noël L; Detry R; Navez B; Brichard SM
    Int J Obes (Lond); 2013 Jun; 37(6):874-80. PubMed ID: 22868830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreasing CB
    Jourdan T; Nicoloro SM; Zhou Z; Shen Y; Liu J; Coffey NJ; Cinar R; Godlewski G; Gao B; Aouadi M; Czech MP; Kunos G
    Mol Metab; 2017 Nov; 6(11):1517-1528. PubMed ID: 29107297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of cannabinoid 1 receptor in beta cells protects against high-fat/high-sugar diet-induced beta cell dysfunction and inflammation in murine islets.
    González-Mariscal I; Montoro RA; Doyle ME; Liu QR; Rouse M; O'Connell JF; Santa-Cruz Calvo S; Krzysik-Walker SM; Ghosh S; Carlson OD; Lehrmann E; Zhang Y; Becker KG; Chia CW; Ghosh P; Egan JM
    Diabetologia; 2018 Jun; 61(6):1470-1483. PubMed ID: 29497784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral cannabinoid 1 receptor blockade mitigates adipose tissue inflammation via NLRP3 inflammasome in mouse models of obesity.
    Han JH; Shin H; Rho JG; Kim JE; Son DH; Yoon J; Lee YJ; Park JH; Song BJ; Choi CS; Yoon SG; Kim IY; Lee EK; Seong JK; Kim KW; Kim W
    Diabetes Obes Metab; 2018 Sep; 20(9):2179-2189. PubMed ID: 29740969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel mouse and rat CB1R isoforms and in silico modeling of human CB1R for peripheral cannabinoid therapeutics.
    Liu QR; Huang NS; Qu H; O'Connell JF; Gonzalez-Mariscal I; Santa-Cruz-Calvo S; Doyle ME; Xi ZX; Wang Y; Onaivi ES; Egan JM
    Acta Pharmacol Sin; 2019 Mar; 40(3):387-397. PubMed ID: 30202012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox.
    Dao M; François H
    Front Endocrinol (Lausanne); 2021; 12():720734. PubMed ID: 34305821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.